Moderna announced first participant dosed in phase 2 study of Omicron-specific booster candidate and publication of data
On Jan. 26, 2022, Moderna announced that the first participant had been dosed in the Phase 2 study…
On Jan. 26, 2022, Moderna announced that the first participant had been dosed in the Phase 2 study…
On Jan. 26, 2022, a former University of British Columbia post-doctoral research fellow led an international research team…
On Jan. 25. 2022, a report published in PNAS provided strong evidence of extensive SARS-CoV-2 infection of white-tailed…
On Jan. 25, 2022, the U.S. Department of Agricultureメs National Veterinary Services Laboratories announced a study with zoos…
On Jan. 25, 2022, researchers at the University of Missouri announced they had identified the highly prevalent, specific…
On Jan. 25, 2022, Pfizer and BioNTech announced the initiation of a clinical study to evaluate the safety,…
On Jan. 25, 2022, Cepheid announced that Health Canada had issued Cepheid a medical device license for Xpert…
The Evolution of CRISPR illustrates its climb out of the primordial ocean on the backs of eukaryotic cells…
On Jan. 24, 2022, Pfizer and BioNTech announced the publication of new results from two laboratory studies demonstrating…
On Jan. 24, 2022, Atara Biotherapeutics, a leader in T-cell immunotherapy, announced that it had leveraged its novel…
On Jan. 24, 2022, Anixa Biosciences announced that the company and its partner, MolGenie, had synthesized a compound…
On Jan. 24, 2022, the University of Oxford announced that a third booster dose of either the ChAdOx1…
On Jan. 20, 2022, Gilead Sciences announced that the U.S. Food and Drug Administration had granted expedited approval…
On Jan. 20, 2022, scientists from the National Institute of Allergy and Infectious Diseases (NIAID) announced that they…
On Jan. 20, 2022, the National Institutes of Health announced it was awarding $170 million over five years,…
On Jan. 20, 2022, a clinical trial funded by the National Institutes of Health found that giving peanut…
On Jan. 19, 2022, Novavaxa announced that Australia’s Therapeutic Goods Administration had granted approval for provisional registration of…
On Jan. 18, 2022, Sorrento Therapeutics announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed…
On Jan. 18, 2021, Humanigen announced a peer-reviewed publication in the Journal of Medical Economics citing the clinical…
On Jan. 18, 2022, Merck and Ridgeback Biotherapeutics announced the signing of a long-term supply agreement with the…
On Jan. 17, 2022, Our Future Health announced the launch of UKメs largest ever health research programme to…
On Jan. 16, 2022, the WHO announced that it had shipped 1.1 million COVID-19 vaccines to Rwanda on…
On Jan. 14, 2022, the U.S. Department of Agriculture’s (USDA) National Veterinary Services Laboratories confirmed a highly pathogenic…
On Jan. 14, 2022, the WHO announced that it had recommended two new drugs for COVID-19, providing yet…
On Jan. 13, 2022, the Centers for Disease Control and Prevention announced a study published in the journal…
On Jan. 13, 2022, OraSure Technologies that its InteliSwabᆴ COVID-19 rapid tests detected the Omicron variant as effectively…
On Jan. 14, 2022, the U.S. Department of Defense, in coordination with the U.S. Department of Health and…
On Jan. 12, 2022, Novavax and SK bioscience, a vaccine business subsidiary of Korea-based SK Group, announced that…
On Jan. 12, 2022, Pfizer announced positive top-line results from a Phase 3 study describing the safety and…
On Jan. 11, 2022, Pfizer and BioNTech announced that the U.S. Food and Drug Administration had expanded the…